ArticleInternational journal of surgery case reports2026
Extraordinary enlargement of the main pancreatic duct dilatation in pancreatic ductal adenocarcinoma - a case report.
Article in International journal of surgery case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, often presenting with nonspecific symptoms and late diagnosis. The global incidence of pancreatic cancer has increased by approximately 9% from 1990 to 2021, with the highest rates observed in high-SDI regions and the lowest in low-SDI regions. A dilated main pancreatic duct (MPD) is a known indicator of malignancy and plays a significant role in surgical planning and outcomes. Case Presentation: We report a rare case of a 50-year-old woman with PDAC presenting with extraordinary MPD dilatation measuring 2 cm. The patient exhibited symptoms of abdominal pain and obstructive jaundice. Imaging revealed a pancreatic head mass with ductal and biliary obstruction, accompanied by intraductal calcification. She underwent a pancreaticoduodenectomy (PD) with duct-to-mucosa pancreaticojejunostomy (PJ), facilitated by the firm consistency of the pancreas and the markedly dilated MPD. Histopathology confirmed a well-differentiated stage 1B PDAC with no lymphovascular invasion. Postoperative recovery was uneventful, and the patient completed adjuvant chemotherapy with a complete response based on RECIST criteria. Discussion: PD is the standard treatment for resectable PDAC, though it carries high complication risks, especially postoperative pancreatic fistula (POPF). This case highlights successful duct-to-mucosa PJ in a patient with favorable anatomy, minimizing POPF risk. Postoperative drain monitoring showed no POPF, and the patient had an excellent recovery. Adjuvant chemotherapy was administered to reduce recurrence risk due to potential micro-metastatic disease. Conclusion: This case illustrates the surgical advantage provided by significant dilatation of the MPD in PDAC, which can reduce the risk of POPF and improve patient outcomes. Early detection and appropriate surgical technique are critical in the management of PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.